Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac
Open Access
- 21 September 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (9), 3034
- https://doi.org/10.3390/jcm9093034
Abstract
Background: To evaluate the clinical course of pseudophakic cystoid macular edema (PCME) treated with topical non-steroidal anti-inflammatory drugs (NSAIDs). Methods: An analysis of the clinical course of PCME consisting of 536 eyes of 536 patients from five consecutive randomized clinical trials aimed at the optimization of anti-inflammatory medication in patients undergoing routine cataract surgery. PCME was classified as (i) grade 0a; no macular thickening, (ii) grade 0b; macular thickening (central subfield macular thickness (CSMT) increase of at least 10%) without signs of macular edema, (iii) grade I; subclinical PCME, (iv) grade II; acute PCME, (v) grade III; long-standing PCME. Eyes with PCME classification from grade I onwards were treated with nepafenac 1 mg/mL t.i.d. for two months. Results: CSMT increase of at least 10% at any postoperative timepoint with cystoid changes—a criterion for PCME—was found in 19 of 536 eyes (total incidence 3.5%). Of these 19 eyes, 13 eyes (total incidence 2.4%) had clinically significant PCME. PCME was considered clinically significant when both of the following visual acuity criteria were fulfilled. At any timepoint after the cataract surgery both the corrected distance visual acuity (CDVA) gain was less than 0.4 decimals from that of preoperative CDVA, and the absolute CDVA level remained below 0.8 decimals. Only one of the 19 eyes with criteria for PCME (total incidence 0.2%, incidence of PCME eyes 5.3%) showed no macular edema resolution within 2 months after topical nepafenac administration. Conclusions: PCME in most cases is self-limiting using topical nepafenac without any further need for intravitreal treatment.This publication has 42 references indexed in Scilit:
- Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study GroupInternational Ophthalmology, 2012
- Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema: The Pan-American Collaborative Retina Study Group ResultsOphthalmology, 2009
- Incidence of Cystoid Macular Edema after Cataract Surgery in Patients with and without Uveitis Using Optical Coherence TomographyAmerican Journal of Ophthalmology, 2009
- Etiology and Treatment of Macular EdemaAmerican Journal of Ophthalmology, 2009
- SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB FOR PSEUDOPHAKIC CYSTOID MACULAR EDEMARetina, 2009
- Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edemaJournal of Cataract & Refractive Surgery, 2008
- INTRAOCULAR TRIAMCINOLONE ACETONIDE FOR PSEUDOPHAKIC CYSTOID MACULAR EDEMARetina, 2007
- Effect of uncomplicated phacoemulsification on the central retina in diabetic and non-diabetic subjectsAlbrecht von Graefes Archiv für Ophthalmologie, 2006
- Macular edemaSurvey of Ophthalmology, 2004
- Macular edemaSurvey of Ophthalmology, 2004